Market capitalization | $2.09m |
Enterprise Value | $143.58m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-25.05m |
Free Cash Flow (TTM) Free Cash Flow | $-29.95m |
Cash position | $10.75m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Galera Therapeutics Inc:
1 Analyst has issued a forecast Galera Therapeutics Inc:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.24 -0.24 |
167%
167%
|
|
EBITDA | -25 -25 |
56%
56%
|
EBIT (Operating Income) EBIT | -25 -25 |
56%
56%
|
Net Profit | -29 -29 |
59%
59%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The firm involves in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. Its product candidate, GC4419, reduces severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
Head office | United States |
CEO | J. Sorensen |
Employees | 7 |
Founded | 2009 |
Website | www.galeratx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.